Mechanism of Action
Watch to learn about the mechanism of action for TABRECTA® (capmatinib) tablets. Based on in vitro/in vivo studies. Preclinical activity does not correlate with clinical outcomes.
Testing: A Strong Start to mNSCLC Diagnosis
Hear a nurse navigator's perspective on how comprehensive biomarker testing can give patients a strong start to diagnosis in mNSCLC.
TABRECTA: An Overview and Deep Dive Into the GEOMETRY mono-1 Trial
Watch a renowned clinical expert provide a detailed review of TABRECTA® (capmatinib) tablets, including the role of METex14 in NSCLC pathogenesis, the GEOMETRY mono-1 trial, patient identification, and AE management.